- Details
- Zach Klaassen interviews Neal Shore about the EMBARK trial's post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis show...
|
- Details
- Matthew Cooperberg, alongside patient advocates Stan Rosenfeld, Bruce Zweig, Nathan Roundy, and Leszek Izdebski, engages in a comprehensive Q&A session with Neal Shore, Stephen Freedland, and Rana McKay. They explore the potential applications of enzalutamide for low-risk prostate cancer patients on active surveillance, referencing findings from the ENACT and EMBARK trials. Dr. Shore emphasizes th...
|
- Details
- Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland an...
|
- Details
- Alicia Morgans speaks with Neal Shore about managing biochemical recurrence (BCR) in high-risk patients, particularly following radiotherapy (RT) and radical prostatectomy (RP). Discussing findings from the EMBARK trial, Dr. Shore emphasizes that combining enzalutamide with LHRH, or using enzalutamide alone, significantly improves metastasis-free survival compared to leuprolide monotherapy. He foc...
|
- Details
- Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free surviva...
|
- Details
- Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the approach of using Enzalutamide, both in combination with Leuprolide and as monotherapy, highlighting its significant impact on metastasis-free survival. The study reveals that combination therapy substantially reduces the...
|
- Details
- In this review, Jason Efstathiou and Alicia Morgans discuss challenges associated with Biochemical recurrence (BCR) management and explore the potential benefits and opportunities of multidisciplinary care (MDC) and treatments based on optimizing risk stratification. Biographies: Jason A. Efstathiou, MD, DPhil, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical Schoo...
|
- Details
- Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...
|
- Details
- Zach Klaassen hosts a high-level discussion with Christian Gratzke about the potential practice-changing outcomes of the EMBARK trial, specifically the impressive results of intensified treatment in high-risk patients. Dr. Gratzke suggests that intermittent hormone treatment could also be effective. The conversation also touches on enzalutamide monotherapy as a standalone treatment and how its suc...
|
- Details
- Neal Shore discusses the EMBARK trial with Alicia Morgans. The study investigated whether enzalutamide plus leuprolide treatment or enzalutamide monotherapy could prolong metastasis-free survival compared with placebo plus leuprolide for men with high-risk biochemical relapse. The study's primary endpoint was met, with patients in the combination arm showing a 58% reduction in the risk of metastas...
|
